Vera Therapeutics (NASDAQ:VERA) receives a new price target of $64.00 from Guggenheim

2 min read | October 30, 2024 03:45 AM PDT | By Team Kalkine Media

Google News:

Vera Therapeutics (NASDAQ:VERA) receives a new price target of $64.00 from Guggenheim — Image source: Shutterstock

Recent News

Why Moderna Is Capturing Market Attention Again?

Eli Lilly Coverage Buzz Keeps Healthcare Market Attention High

Sandisk Gains Attention As an AI-Driven Growth Stock

Why Micron Technology Is Benefiting From the AI Growth Wave?

Make Kalkine Media
My Trusted Source

Highlights

Guggenheim has raised its price objective for Vera Therapeutics from $56 to $64, indicating potential upside for the stock.
The company specializes in developing treatments for serious immunological diseases, with its lead product candidate currently in Phase III trials.
Institutional ownership is significant, with nearly all stock held by institutional investors, reflecting strong interest in the company's potential.

Vera Therapeutics (NASDAQ:VERA) recently received an upward adjustment to its price objective from Guggenheim, which increased its estimate from $56 to $64. This adjustment is based on the firm’s continued positive outlook on the stock, maintaining a "buy" rating. The new price objective suggests a potential upside of nearly 49% from the stock's previous close.

In addition to Guggenheim's assessment, several other analysts have recently provided insights on Vera Therapeutics. Scotiabank initiated coverage with a "sector outperform" rating and a price objective of $60. Cantor Fitzgerald reaffirmed its "overweight" rating with a significantly higher price objective of $107. Evercore ISI also upgraded the stock to a "strong-buy" rating. Meanwhile, JPMorgan Chase & Co. raised its price objective from $62 to $72. The overall sentiment from analysts indicates that the stock is viewed positively, with one hold rating, seven buy ratings, and two strong buy ratings.

Vera Therapeutics operates as a clinical-stage biotechnology company focused on developing and commercializing therapies for severe immunological conditions. The company's lead candidate, atacicept, is currently undergoing Phase III clinical trials for immunoglobulin A nephropathy and Phase II trials for lupus nephritis. The potential success of these trials could significantly enhance the company’s position in the market.

As of the latest market data, shares of Vera Therapeutics opened at $42.97, with a market capitalization of approximately $2.36 billion. The stock has shown volatility, with a 12-month low of $9.68 and a high of $50.78. The company's strong institutional backing, along with its promising pipeline of therapies, positions it favorably in the biotechnology sector, particularly in the field of immunological diseases.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.